Sign up
Pharma Capital

Zelda Therapeutics closing in on development of autism clinical trial

Dr Stewart Washer, executive director of Zelda Therapeutics Ltd (ASX:ZLD), discusses with Proactive the successful results from their recent observation autism trial in Chile.

The results showed that in a group of 21 patients cannabis extracts were significantly more effective than conventional medicines used, including atypical antipsychotics, and these extracts were well tolerated by the patients overall.

 

View full ZLD profile

Zelda Therapeutics Ltd Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.